TY - JOUR
T1 - Ovarian cancer cells commonly exhibit defective STING signaling which affects sensitivity to viral oncolysis
AU - De Queiroz, Nina Marí Gual Pimenta
AU - Xia, Tianli
AU - Konno, Hiroyasu
AU - Barber, Glen N.
N1 - Funding Information:
The authors thank Dr. Xiang-Xi Xu for providing the ovarian cancer cell lines. This work was supported by the following founding sources: University of Miami/Sylvester Comprehensive Cancer Center Grant entitled "Analysis of STING and Evaluation of STING Based Therapeutics in Ovarian Cancer" and NIH/NCI (RO1CA194404-01). de Queiroz was partially supported by Science without Borders fellowship from the National Council for Scientific and Technological Development (CNPq/Brazil).
PY - 2019
Y1 - 2019
N2 - Ovarian cancer is the sixth most prevalent cancer in women and the most lethal of the gynecologic malignancies. Treatments have comprised the use of immunotherapeutic agents as well as oncolytic viruses, with varying results for reasons that remain to be clarified. To better understand the mechanisms that may help predict treatment outcome, we have evaluated innate immune signaling in select ovarian cancer cell lines, governed by the Stimulator of Interferon Genes (STING), which controls self or viral DNA-triggered cytokine production. Our results indicate that STING-dependent signaling is habitually defective in majority of ovarian cancer cells examined, frequently through the suppression of STING and/or the cyclic dinucleotide (CDN) enzyme Cyclic GMP-AMP synthase (cGAS) expression, by epigenetic processes. However, STINGindependent, dsRNA-activated innate immune cytokine production, which require RIG-I/MDA5, were largely unaffected. Such defects enabled ovarian cancer cells to avoid DNA damage-mediated cytokine production, which would alert the immunosurveillance system. Loss of STING signaling also rendered ovarian cancer cells highly susceptible to viral oncolytic g34.5 deleted-HSV1 (Herpes simplex virus) infection in vitro and in vivo. Implications: STING signaling evaluation in tumors may help predict disease outcome and possibly dictate the efficacy of oncoviral and other types of cancer therapies.
AB - Ovarian cancer is the sixth most prevalent cancer in women and the most lethal of the gynecologic malignancies. Treatments have comprised the use of immunotherapeutic agents as well as oncolytic viruses, with varying results for reasons that remain to be clarified. To better understand the mechanisms that may help predict treatment outcome, we have evaluated innate immune signaling in select ovarian cancer cell lines, governed by the Stimulator of Interferon Genes (STING), which controls self or viral DNA-triggered cytokine production. Our results indicate that STING-dependent signaling is habitually defective in majority of ovarian cancer cells examined, frequently through the suppression of STING and/or the cyclic dinucleotide (CDN) enzyme Cyclic GMP-AMP synthase (cGAS) expression, by epigenetic processes. However, STINGindependent, dsRNA-activated innate immune cytokine production, which require RIG-I/MDA5, were largely unaffected. Such defects enabled ovarian cancer cells to avoid DNA damage-mediated cytokine production, which would alert the immunosurveillance system. Loss of STING signaling also rendered ovarian cancer cells highly susceptible to viral oncolytic g34.5 deleted-HSV1 (Herpes simplex virus) infection in vitro and in vivo. Implications: STING signaling evaluation in tumors may help predict disease outcome and possibly dictate the efficacy of oncoviral and other types of cancer therapies.
UR - http://www.scopus.com/inward/record.url?scp=85063756562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063756562&partnerID=8YFLogxK
U2 - 10.1158/1541-7786.MCR-18-0504
DO - 10.1158/1541-7786.MCR-18-0504
M3 - Article
C2 - 30587523
AN - SCOPUS:85063756562
VL - 17
SP - 974
EP - 986
JO - Molecular Cancer Research
JF - Molecular Cancer Research
SN - 1541-7786
IS - 4
ER -